News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|November 24, 2020

v

Episodes in this series

EP. 1 v

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

The Right Way to Avoid Malpractice Lawsuits

ByWilliam H. Reid, MD, MPH,Skip Simpson, JD

September 30th 2020

Looking to the Future and Improving Patient Care

ByMichelle Riba, MD, MS, DFAPA, FAPM,Luigi Grassi, MD

August 31st 2020

Case-Based Clinical Approaches for Clinicians

ByLawrence E. Kaplan, DO

August 31st 2020

Finding Meaning in the Face of Suffering

ByWendy G. Lichtenthal, PhD,Kailey E. Roberts, PhD,Hayley Pessin, PhD,Allison Applebaum, PhD,William Breitbart, MD

August 31st 2020

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Empowering Patients and Expanding Formulation Options in Schizophrenia Care